Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Ikenberg, Kristian ^a   Fritzsche, Florian R ^a   Zuerrer Haerdi, Ursina ^a   Hofmann, Irina ^a   Hermanns, Thomas ^a   Seifert, Helge ^a   Müntener, Michael ^a   Provenzano, Maurizio ^a   Sulser, Tullio ^a   Behnke, Silvia ^a   Gerhardt, Josefine ^a   Mortezavi, Ashkan ^a   Wild, Peter ^a   Hofstädter, Ferdinand ^b   Burger, Maximilian ^b   Moch, Holger ^a   Kristiansen, Glen ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN LIKE GROWTH FACTOR II MRNA BINDING PROTEIN 3; ONCOFETAL ANTIGEN; PROSTATE SPECIFIC ANTIGEN; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; IMP3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREOPERATIVE EVALUATION; PRIMARY TUMOR; PROGNOSIS; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; SURVIVAL TIME; TISSUE MICROARRAY; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RNA-BINDING PROTEINS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 77954061302     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-341     Document Type: Article

References (30)

1. Vikesaa J, Hansen TV, Jonson L, Borup R, Wewer UM, Christiansen J, Nielsen FC. RNA-binding IMPs promote cell adhesion and invadopodia formation. Embo J 2006, 25(7):1456-1468. 10.1038/sj.emboj.7601039, 1440323, 16541107.
2. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999, 19(2):1262-1270. 116055, 9891060.
3. Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005, 280(18):18517-18524. 10.1074/jbc.M500270200, 15753088.
4. Monk D, Bentley L, Beechey C, Hitchins M, Peters J, Preece MA, Stanier P, Moore GE. Characterisation of the growth regulating gene IMP3, a candidate for Silver-Russell syndrome. J Med Genet 2002, 39(8):575-581. 10.1136/jmg.39.8.575, 1735212, 12161597.
5. Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knochel W, Adler G, Gress TM. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999, 88(1):95-99. 10.1016/S0925-4773(99)00160-4, 10525192.
6. Noske A, Faggad A, Wirtz R, Darb-Esfahani S, Sehouli J, Sinn B, Nielsen FC, Weichert W, Buckendahl AC, Roske A, et al. IMP3 expression in human ovarian cancer is associated with improved survival. Int J Gynecol Pathol 2009, 28(3):203-210. 10.1097/PGP.0b013e318189a724, 19620937.
7. Bellezza G, Cavaliere A, Sidoni A. IMP3 expression in non-small cell lung cancer. Hum Pathol 2009, 40(8):1205-1206. 10.1016/j.humpath.2009.03.019, 19427669.
8. Xu H. IMP3: a diagnostic and prognostic biomarker in malignant melanoma. Expert Rev Mol Diagn 2008, 8(5):557-558. 10.1586/14737159.8.5.557, 18785801.
9. Do SI, Kim YW, Park HR, Park YK. Expression of insulin-like growth factor-II mRNA binding protein 3 (IMP3) in osteosarcoma. Oncol Res 2008, 17(6):269-272. 10.3727/096504008786991639, 19192721.
10. Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS, Owen DA. Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer 2010, 10:59. 10.1186/1471-2407-10-59, 2837867, 20178612.
11. Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol 2010,
12. Findeis-Hosey JJ, Yang Q, Spaulding BO, Wang HL, Xu H. IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol 2010, 41(4):477-484. 10.1016/j.humpath.2009.10.004, 20004948.
13. Mentrikoski MJ, Ma L, Pryor JG, McMahon LA, Yang Q, Spaulding BO, Scott GA, Wang HL, Xu H. Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes. Mod Pathol 2009, 22(12):1582-1587. 10.1038/modpathol.2009.128, 19734845.
14. Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM. Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol 2009, 16(6):1711-1719. 10.1245/s10434-009-0446-0, 19357927.
15. Li L, Xu H, Spaulding BO, Cheng L, Simon R, Yao JL, di Sant'Agnese PA, Bourne PA, Huang J. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol 2008, 39(8):1205-1211. 10.1016/j.humpath.2007.12.012, 18547613.
16. Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol 2007, 20(12):1263-1268. 10.1038/modpathol.3800960, 17885673.
17. Simon R, Bourne PA, Yang Q, Spaulding BO, di Sant'Agnese PA, Wang HL, Xu H. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol 2007, 38(8):1178-1183. 10.1016/j.humpath.2007.02.001, 17521698.
18. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A. Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol 2009, 20(3):149-157. 10.1007/s12022-009-9079-x, 19449140.
19. Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol 2009, 40(11):1528-1533. 10.1016/j.humpath.2009.05.005, 19695680.
20. Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G, et al. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol 2009, 16(12):3499-3506. 10.1245/s10434-009-0648-5, 19672661.
21. Kobel M, Xu H, Bourne PA, Spaulding BO, Shih Ie M, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol 2009, 22(3):469-475. 10.1038/modpathol.2008.206, 19136932.
22. Lu D, Vohra P, Chu PG, Woda B, Rock KL, Jiang Z. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol 2009, 33(4):521-525. 10.1097/PAS.0b013e31818aada9, 19047899.
23. Riener MO, Fritzsche FR, Clavien PA, Pestalozzi BC, Probst-Hensch N, Jochum W, Kristiansen G. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Hum Pathol 2009, 40(10):1377-1383. 10.1016/j.humpath.2009.01.024, 19467694.
24. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57(1):43-66. 10.3322/canjclin.57.1.43, 17237035.
25. Carroll PR. Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both?. J Urol 2005, 173(4):1061-1062. 10.1097/01.ju.0000156838.67623.10, 15758699.
26. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 2006, 175(4):1337-1340. 10.1016/S0022-5347(05)00734-2, 16515993.
27. Nilsson KP, Ikenberg K, Aslund A, Fransson S, Konradsson P, Rocken C, Moch H, Aguzzi A. Structural typing of systemic amyloidoses by luminescent-conjugated polymer spectroscopy. Am J Pathol 176(2):563-574. 10.2353/ajpath.2010.080797, 20035056.
28. Nielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl 2001, 234:93-99.
29. Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004, 58(2):183-192. 10.1002/pros.10324, 14716744.
30. Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E, Anthony S, Vukelja S, Berman B, Tully H, et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 2006, 13(6):1185-1191. 10.1016/j.ymthe.2006.01.013, 16581300.